LEO Pharma Articles
LEO Pharma and 4SC Discovery link for skin disease research
26 February 2013
LEO Pharma sales reps file suit on overtime in USA
9 February 2012
LEO Pharma gets FDA nod for Picato
29 January 2012
LEO Pharma in over $300 million deal for psoriasis therapy
10 January 2012
Two Danish drugmakers - Novo Nordisk and LEO Pharma - say “no” to Greek price cuts order
1 June 2010
Pharmaceutical M&A deals in 2009
4 February 2010
LEO Pharma to Acquire Peplin for $287.5 million
3 September 2009
GTC pursuing legal action against LEO
23 March 2009
LEO Pharma sets up company in China
15 December 2008
GTC's 3rd-qtr net loss narrows to $6.1M
17 November 2008
Leo gets EMEA approval for Xamiol gel
6 October 2008
Leo could save UK L66M with psoriasis-modelling software
29 September 2008
GTC completes BLA filing for ATryn
18 August 2008
GTC's ATryn granted orphan status by FDA
17 December 2007
Daiichi Sankyo strengthens UK marketing team
17 September 2007
ATryn introduced at ISTH conference
26 July 2007
MA for GTC Bio's ATryn goes to Leo
8 January 2007
Galapagos R&D accord with LEO Pharma
6 November 2006
Leo Pharma sees $779M turnover in 2005
17 April 2006
New Warner Chilcott posts 1st-qtr loss
11 July 2005
Canadian Rx spending slows in 2004: PMPRB
27 June 2005
Alliance explores Oxygent proof-of-concept study
30 May 2005
Alliance and LEO in Oxygent accord
7 March 2005
LEO Pharma and Stiefel Labs sign marketing deal
17 January 2005
Alliance and LEO to co-develop Oxygent
10 January 2005
Denmark's Leo Pharma revamps French site
5 July 2004
Dutch Government Reimbursement Blacklist Rises To 35
9 December 1996
Showing 1-31 of 31 articles
- 1
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
